Tonix Pharmaceuticals, Inc.
509 Madison Ave.
Suite 306
New York
New York
10022
United States
Tel: 212-980-9155
Fax: 212-923-5700
Website: http://www.tonixpharma.com/
304 articles with Tonix Pharmaceuticals, Inc.
-
Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs
11/23/2021
Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to support the initiation of a Phase 2 study of TNX-1900* (intranasal potentiated oxytocin) for the prevention of migraine headache in chronic migraineurs.
-
Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022.
-
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
11/22/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight.
-
Tonix Pharmaceuticals to Present at the Q4 Investor Summit
11/12/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the Q4 Investor Summit on November 17, 2021, at 4:50 p.m. ET.
-
Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021
11/9/2021
Tonix Pharmaceuticals Holding Corp. today announced a poster presentation of results from its open-label, Phase 1 clinical study of TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablets).
-
Tonix Pharmaceuticals to Participate in BIO-Europe Digital 2021
10/21/2021
Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the BIO-Europe 2021 event, being held virtually October 25-28, 2021.
-
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
10/7/2021
Tonix Pharmaceuticals Holding Corp. , announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to participate in a panel discussion at the A.G.P. Fall Virtual Biotech & Specialty Pharma Conference on October 13, 2021.
-
Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland
10/4/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center located in Frederick, Md.
-
Tonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021
9/27/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announces the acceptance and details of an oral presentation at the American College of Rheumatology Convergence 2021.
-
Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
9/23/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it has expanded its research collaboration with Columbia University.
-
Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
9/22/2021
Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 2:00 p.m. ET.
-
Tonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
9/7/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
-
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
8/24/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it received the official minutes from a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration to develop TNX-102 SL1 as a potential treatment for Long COVID Syndrome, which is now known officially as Post-Acute Sequelae of COVID-19.
-
Shares of Tonix Pharmaceuticals were up nearly 11% in premarket trading after the company announced plans to initiate a Phase II study of TNX-102 SL as a potential treatment for Long COVID Syndrome following a positive meeting with the U.S. FDA.
-
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
8/2/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it will hold a groundbreaking ceremony at the Company’s planned 45,000 square foot clinical scale manufacturing facility in the New Bedford Business Park in Massachusetts on August 3, 2021 at 11:00 a.m. ET.
-
Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs
7/27/2021
Tonix Pharmaceuticals Holding Corp. announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.
-
Tonix Pharmaceuticals Announces New Board Member, Carolyn E. Taylor
7/19/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the appointment of Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.
-
Tonix Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes
6/28/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opens, June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.
-
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
6/21/2021
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome which is now known officially as Post-Acute Sequelae of COVID-19.
-
The U.S. CDC issued new guidance for long COVID, and the NIH is figuring out how to deal with the disease, while Tonix Pharma plans to develop TNX-102 SL.